Muhammad Tariq, MD
Interventional Cardiology · Greenville, NCNPI 1124374939
Payments from drug & device makers
Across 242 payments — averaging $66.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$9K
- Abiomed$2K
- Boston Scientific$1K
- Abbott$978
- E.r. Squibb & Sons, L.L.C.$495
- Recor Medical Inc$392
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$4,75030%
- Travel & lodging$3,38521%
- Food & beverage$7,76048%
- Education$1441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 20 | $8,668 |
| Abiomed | 38 | $1,634 |
| Boston Scientific | 14 | $1,170 |
| Abbott | 21 | $978 |
| E.r. Squibb & Sons, L.L.C. | 46 | $495 |
| Recor Medical Inc | 6 | $392 |
| Medtronic(2 entities) | 3 | $373 |
| Novartis | 22 | $352 |
| Shockwave Medical, Inc | 4 | $300 |
| Amgen | 19 | $291 |
| Stryker | 3 | $264 |
| Pfizer | 7 | $127 |
| Johnson & Johnson | 6 | $124 |
| Penumbra, Inc. | 2 | $124 |
| Cardiovascular Systems Inc. | 1 | $120 |
| Angiodynamics, Inc. | 2 | $114 |
| Merck | 3 | $64 |
| Edwards Lifesciences | 3 | $61 |
| Irhythm Technologies, Inc. | 2 | $60 |
| Chiesi USA, Inc. | 4 | $56 |
| AstraZeneca | 4 | $49 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Boehringer Ingelheim | 2 | $38 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Terumo Medical Corporation | 1 | $26 |
| Astellas Pharma US Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Teleflex LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$8,273
- CT THROMBECTOMY SYSTEM KIT$8,273
- Diamondback Coronary$476
- AVVIGO Guidance System$372
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$254
- Rotablator Rotational Atherectomy System Console Kit$250
- Paradise Ultrasound Renal Denervation System$184
- SYNERGY$175
- FlowTriever$154
- SYMPLICITY G3$148
- Impella$146
- TurboHawk$138
- OPTIS$132
- PARADISE RENAL DENERVATION SYSTEM$114
- Auryon Laser System 100-120 Vac$102
How this compares
$16,040 in reported general payments places this provider in the 55th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $105,885 |
| Repatha SureclickEvolocumab | 157 | $103,248 |
| EntrestoSacubitril/Valsartan | 42 | $44,450 |
| XareltoRivaroxaban | 41 | $25,141 |
| BrilintaTicagrelor | 37 | $19,934 |
| FarxigaDapagliflozin Propanediol | 18 | $13,104 |
| VascepaIcosapent Ethyl | 14 | $6,508 |
| Ranolazine ErRanolazine | 73 | $5,048 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 207 | $2,774 |
| Metoprolol Succinate | 277 | $2,581 |
| Atorvastatin Calcium | 189 | $1,579 |
| ClopidogrelClopidogrel Bisulfate | 127 | $1,285 |
| Midodrine Hcl | 23 | $1,043 |
| Amlodipine Besylate | 175 | $950 |
| Rosuvastatin Calcium | 103 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $127 | $105,885125 claims |
| NovartisEntresto | $352 | $44,45042 claims |
| AstraZenecaBrilinta, Farxiga | $49 | $33,03855 claims |
| Johnson & JohnsonXarelto | $124 | $25,14141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Greenville
- Paul MahoneyGreenville$3.9M
- Eric CarlsonGreenville$100K
- Dennis MorrisGreenville$36K
- Ravish SacharRaleigh$10.1M
- George AdamsGarner$5.2M
- Oluseun AlliCharlotte$2.3M
- Patrick SimpsonPinehurst$1.6M
- Matthew CavenderChapel Hill$1.5M
- Rajesh SwaminathanDurham$1.4M
- Steven FilbyPinehurst$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.